The CA19-9 IRMA system provides a direct in vitro quantitative determination of the cancer associated antigen CA19-9 in human serum in the range of 0-240 U/mL.
Each kit contains material sufficient for 100 or 50 assay tubes, permitting the construction of one standard curve and the assay of 42 (RK-199CT) or 17 (RK-199CT50) unknowns in duplicate.
CA19-9 is a tumour associated mucin-type high molecular weight glycoprotein antigen circulating in the blood and can be found in tissues. This test is useful in monitoring patients with confirmed pancreatic cancer whose CA19-9 levels are above the cut off at the time of the diagnosis. Patients negative for the Lewis blood group antigen have no CA 19-9 in their blood even in the presence of malignant disease.